Pure Global
NCT04615468

A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）

A Single-arm, Open-label, Multi-center, Phase II Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
TQ-B3525
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Location
Beijing,Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2020
End date
Oct 31, 2022
Enrollment
78 participants
Primary outcome

Overall response rate (ORR) by Independent Review Committee

Summary

This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with
 relapse/refactory peripheral T-cell lymphoma who have received at least 1 lines of
 therapeutic schedules. TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04615468
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04615468 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is currently Not yet recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 78 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.